Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Editors Pick
    • Materiovigilance-...

    Materiovigilance- Monitor all Adverse Reaction to Medical Devices, CDSCO directs State Drug Controllers

    Medical Dialogues BureauWritten by Medical Dialogues Bureau Published On 1 Dec 2019 8:30 AM  |  Updated On 1 Dec 2019 8:30 AM

    New Delhi: Through a recent notification, the Central Drugs Standard Control Organisation (CDSCO) has informed all the State Drug Controllers about its move to step up Materiovigilance Programme of India (MvPI) in the country and direct them to encourage all clinicians and healthcare professionals to mandatorily adopt reporting of medical devices adverse event to MvPI-Indian Pharmacopoeia Commission (IPC).


    The public notice dated November 26 2019, duly signed by Dr V G Somani, Drugs Controller General of India (DCGI) wrote to all the authorities regarding the strengthening of MvPI.


    "The Indian Pharmacopoeia Commission (IPC), an autonomous institution of Ministry of Health and Family Welfare, Government of India has been entrusted with the responsibility relating to Materiovigilance Program of India (MvPI) since July 6, 2015. The objective of MvPI is to improve patient safety and welfare of the Indian population by monitoring medical devices safety and thereby reducing the risks associated with the use of medical devices," the letter to all state controllers noted


    The issue of adverse events of medical devices has been indeed gaining momentum in the country and so is the authority's response. Earlier this year, pacemakers sold by one of the largest medical device makers, Medtronic was red-flagged by the apex drug regulator Central Drugs Standard Control Organisation (CDSCO) for battery-related malfunction.


    Also Read: Red Flag: CDSCO warns against Medtronic pacemaker for battery-related malfunction


    In the light of such adverse events, the recently rolled out notification by CDSCO regarding Materiovigilance Program is likely to keep track and minimize the adverse impacts of medical devices.


    Materiovigilance (MV) is based on sound scientific principle and is an integral part of effective clinical practices. The discipline needs to develop further to meet the demands of public health for which continuous monitoring of medical devices is essential. Such monitoring will help in assessing, monitoring and detecting adverse effects of medical devices, their malfunctions etc. that can result in higher morbidity and mortality. The measure will help to maximize benefits and minimize the risk associated with medical devices.


    "The Materiovigilance and medical device adverse event reporting among healthcare professionals needs to be scaled up. It can be done by developing educational and promotional interventions like continuous medical education, awareness program, workshops, conferences on Materiovigilance etc," Somani noted


    The authority then directed the state controllers to ensure the stepping up to MvPi In their respective areas

    "In view of the above, you are requested to initiate the steps for strengthening public health by sensitizing and advising all clinicians and other healthcare professional under your jurisdiction to mandatorily -adopt reporting of medical devices adverse event to MvPI-IPC," DCGI stated


    Also Read: Certain Medtronic pacemaker batteries fail without warning; USFDA flags issue
    adverse eventsCDSCODCGIindian pharmacopio commissionIPCmateriovigilancemedical device adverse reactionMedical DevicesMedtronicMvPIpacemakerState Drug ControllerVG Somani

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Medical Dialogues Bureau
    Medical Dialogues Bureau

      Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers.  Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in. Check out more about our bureau/team here

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok